Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Purple Biotech ( (PPBT) ) has shared an announcement.
On June 23, 2025, Purple Biotech announced significant advancements in its novel CAPTN-3 tri-specific antibody platform at the EACR 2025 Annual Congress. The platform, which was presented in a poster session, showcases its ability to engage both T cells and NK cells, leading to enhanced anti-tumor activity. The CAPTN-3 platform’s innovative design, including a unique anti-NKG2A arm, demonstrated promising preclinical results, such as sustained tumor regression in models of triple-negative breast cancer. This advancement highlights Purple Biotech’s potential to strengthen its position in the oncology sector by offering novel therapeutic options that address immune evasion and drug resistance in cancer treatment.
The most recent analyst rating on (PPBT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes products such as CM24, NT219, and CAPTN-3, which target various cancer pathways to enhance immune response and improve treatment outcomes. Purple Biotech is headquartered in Rehovot, Israel.
Average Trading Volume: 107,926
Technical Sentiment Signal: Sell
Current Market Cap: $7.08M
Find detailed analytics on PPBT stock on TipRanks’ Stock Analysis page.